Accepts applications
Can I apply?
Accepts applications
The funder's latest Form 990-PF says it accepts applications. Read the instructions below before you write.
- How to apply
- Deadlines
The funder's latest Form 990-PF says it accepts applications. Read the instructions below before you write.
Application policy: Accepts applications, as stated on the FY2024 return.
These lines count this foundation's own Form 990-PF returns that the IRS has published as data. An amended return replaces its original. They describe past returns only.
Application guidance comes from the funder's own Form 990-PF, Part XV (the section where a private foundation says how to apply), shown as filed. It is the funder's words, not ours. These fields are free text and the IRS form cuts them short. Filers sometimes put whole sentences in the contact-name box. Shown exactly as filed.
Giving by year
Total assets by year
| Year | Form | Revenue | Expenses | Giving | Assets | Net assets |
|---|---|---|---|---|---|---|
| FY2024 | 990-PF | $998,631 | $1,371,889 | $960,916 | $12,710,916 |
Figures are as reported on the e-filed return, with no restatement. Fiscal years are the funder's own tax year, labelled by the calendar year the period ends in. A blank line means the return does not carry that figure; a real zero shows as $0. When an amended return replaces an original, every figure here uses the amended return. The original is not shown. Giving is what the funder actually paid out toward its charitable purpose in the year (qualifying distributions on Form 990-PF, charitable disbursements otherwise). Assets are what it holds; giving is what moves.
Recipient focus areas
Where recipients are
Based on the 28% of grant rows we could match to an organization record. The rest stay as reported. The IRS assigns the NTEE category when it grants exemption. It often reflects the original filing, not today's giving.
| Recipient | Purpose | Amount | Year | Source |
|---|---|---|---|---|
| MOUNT DESERT ISLAND BIOLOGICAL LABORATORYBAR HARBOR, ME | THIS PROJECT SEEKS TO CONTINUE THE PROJECT AWARDED IN 2022 TO ESTABLISH A NOVEL TREATMENT STRATEGY FOR DIABETIC KIDNEY DISEASE. PREVIOUS SUPPORT FROM THE MACKENZIE FOUNDATION IS ALLOWING MDI BIO LAB TO UNDERSTAND THE STRUCTURE AND FUNCTIONAL PARTS OF THE HPA2 MOLECULE AND ESTABLISH A BASELINE FROM WHICH TO FULLY UNDERSTAND ITS FUNCTION. BASED ON THIS ONGOING WORK, MDI BIO LAB NOW SEEKS TO INVESTIGATE THE EFFECT OF DIABETES IN A MODEL ORGANISM OF AGING (AFRICAN TURQUOISE KILLIFISH). SIMULTANEOUSLY, MDI BIO LAB ALSO PROPOSES TO USE THIS MODEL TO STUDY THE LOSS OF PERITUBULAR CAPILLARIES OBSERVED DURING KIDNEY AGING. | $450,000 | 2024 |
Recipients are shown as the funder wrote them on the return. A recipient with a link was matched to an organization record; the rest stay as reported and are never guessed. Some links come from other funders' returns: when three or more of them wrote the same name and state with one EIN, and the city on this row matches, we use that EIN. The name on this row is still shown as this funder wrote it.
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| Scott R Mackenzie | DIRECTOR | 5.00 | $0 |
| Melinda A Mackenzie | DIRECTOR | 3.00 | $0 |
| Lawrence B Mackenzie | DIRECTOR | 5.00 | $0 |
| Julian Fant | DIRECTOR |
From the officer list on the latest e-filed return. Compensation is as reported there; a blank means the return carries no figure.
| $12,688,929 |
| FY2022 | 990-PF | $491,332 | $1,519,129 | $1,200,000 | $13,810,488 | $13,779,640 |
| FY2021 | 990-PF | $1,838,613 | $1,379,498 | $1,008,269 | $14,866,228 | $14,807,436 |
| FY2020 | 990-PF | $491,266 | $1,220,262 | $939,383 | $14,357,687 | $14,342,687 |
| FY2019 | 990-PF | $377,013 | $1,113,484 | $825,000 | $17,006,268 | $17,000,268 |
| FY2018 | 990-PF | $926,411 | $1,215,140 | $946,691 | $17,743,339 | $17,736,739 |
| FY2017 | 990-PF | $990,092 | $1,463,746 | $1,190,203 | $18,030,101 | $18,029,501 |
| FY2016 | 990-PF | $570,426 | $1,371,289 | $994,316 | $18,650,287 | $18,646,912 |
| MOUNT DESERT ISLAND BIOLOGICAL LABORATORYBAR HARBOR, ME | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE GIFT TO SEEK TO PREVENT ORGAN COMPLICATIONS IN DIABETIC PATIENTS. HIGH GLUCOSE LEVELS LEAD TO THE PATHOLOGICAL CHANGES IN THE VASCULATURE OF DIFFERENT ORGANS SUCH AS THE HEART, KIDNEY, EYE AND PERIPHERAL CIRCULATION. THE FOCUS IS THE MICROCIRCULATION OF THE KIDNEY. THE ENDOTHELIAL CELL SURFACE IS COVERED WITH A LAYER OF GLYCOCALYX. THE GLYCOCALYX IS VERY IMPORTANT FOR THE HEALTH OF THE VASCULAR WALL AND REGULATES CENTRAL MECHANISMS SUCH AS METABOLISM, INFLAMMATION, BLOOD PRESSURE, ETC. WE WILL TEST THE HYPOTHESIS THAT RECOMBINANT HPA2 AMELIORATES DIABETIC NEPHROPATHY BY MAINTAINING A FUNCTIONAL HEPARAN SULFATE GLYCOCALYX ON ENDOTHELIAL CELLS AND MONOCYTES. THIS IS A CONTINUATION OF THE PROJECT FUNDED IN 2021. | $450,000 | 2022 |
| MDI BIOLOGICAL LABORATORYMatched to this organization because 3 grant-making charities wrote this name with its EIN. Source: Schedule I of their Form 990 returns, fiscal years 2020 to 2024. Counted Oct 9, 2026.BAR HARBOR, ME | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE FUNDS TO SUPPORT RESEARCH TO DEFINE BOTH A MECHANISM OF ACTION AND A MORE EFFECTIVE TREATMENT PARADIGM IN MOLECULAR STIMULATION OF THE NATURAL REPAIR PROCESSES IN THE HEART AND OTHER TISSUES. | $400,000 | 2019 |
| MOUNT DESERT ISLAND BIOLOGICAL LABORATORYBAR HARBOR, ME | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE GIFT TO PREVENT ORGAN COMPLICATIONS IN DIABETIC PATIENTS. HIGH GLUCOSE LEVELS LEAD TO THE PATHALOGICAL CHANGES IN THE VASCULATURE OF DIFFERENT ORGANS SUCH AS THE HEART, KIDNEY, EYE AND PERIPHERAL CIRCULATION. THE FOCUS IS THE MICROCIRCULATION OF THE KIDNEY. THE ENDOTHELIAL CELL SURFACE IS COVERED WITH A LAYER OF GLYCOCALYX. THE GLYCOCALYX IS VERY IMPORTANT FOR THE HEALTH OF THE VASCULAR WALL AND REGULATES CENTRAL MECHANISMS SUCH AS METABOLISM, INFLAMMATION, BLOOD PRESSURE, ETC. WE WILL TEST THE HYPOTHESIS THAT RECOMBINANT HPA2 AMELIORATES DIABETIC NEPHROPATHY BY MAINTAINING A FUNCTIONAL HEPARAN SULFATE GLYCOCALYX ON ENDOTHELIAL CELLS AND MONOCYTES. | $400,000 | 2021 |
| The Jackson Laboratoryfarmington, CT | The Benefactor desires that Grantee shall use the funds to support a study where patients will be recruited to contribute tumor and gut microbe samples for sequencing to identify involved microbes, and will also develop a mouse model for testing candidates that will have broad utility beyond the scope of this specific project. | $350,000 | 2016 |
| FLORIDA INTERNATIONALMIAMI, FL | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE FUNDS TO SUPPORT CHARACHERIZING SARCOMA MUTATIONS WITH MATCHING DRUGS AND APPROPRIATE TARGETED TREATMENTS BY IMPLEMENTING A COMBINED FUNCTIONAL DRUG SCREENING AND GENOMICS PLATFORM AND SELECTING CLINICALLY APPROVED COMPOUNDS TO OFFER ADVANCED SARCOMA PATIENTS THE SAFEST POSSIBLE CHANCE OF ACHIEVING REMISSIONS AND ULTIMATELY CURING THEIR DISEASE. | $350,000 | 2020 |
| MDI BIOLOGICAL LABORATORYMatched to this organization because 3 grant-making charities wrote this name with its EIN. Source: Schedule I of their Form 990 returns, fiscal years 2020 to 2024. Counted Oct 9, 2026.BAR HARBOR, ME | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE FUNDS TO SUPPORT RESEARCH TO DEFINE BOTH A MECHANISM OF ACTION AND A MORE EFFECTIVE TREATMENT PARADIGM IN MOLECULAR STIMULATION OF THE NATURAL REPAIR PROCESSES IN THE HEART AND OTHER TISSUES. | $350,000 | 2017 |
| CINCINNATI CANCER FOUNDATION INCCINCINNATI, OH | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE GIFT TO ESTABLISH THE ADVANCING PRECISION ONCOLOGY CENTER ("APOC"), WHOSE PURPOSE IS TO ENABLE PATIENT ACCESS TO A WIDE RANGE OF NGS TESTING INTENDED TO FACILITATE EARLY DETECTION, BETTER OUTCOMES, AND BETTER POSSIBILITIES FOR CANCER CURES THROUGH EARLIER DETECTION AND INTERVENTION. | $350,000 | 2022 |
| MDI BIOLOGICAL LABORATORYMatched to this organization because 3 grant-making charities wrote this name with its EIN. Source: Schedule I of their Form 990 returns, fiscal years 2020 to 2024. Counted Oct 9, 2026.BAR HARBOR, ME | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE FUNDS TO SUPPORT RESEARCH TO DEFINE BOTH A MECHANISM OF ACTION AND A MORE EFFECTIVE TREATMENT PARADIGM IN MOLECULAR STIMULATION OF THE NATURAL REPAIR PROCESSES IN THE HEART AND OTHER TISSUES. | $336,691 | 2018 |
| THE JACKSON LABORATORYFARMINGTON, CT | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE FUNDS TO SUPPORT THE IDENTIFICATION OF A POTENTIALLY CURATIVE REGIMEN FOR TANDEM DUPLICATOR PHENOTYPE TRIPLE NEGATIVE BREAST CANCER TO BE TESTED IN A PANEL OF HUMAN TRIPLE NEGATIVE BREAST CANCER TUMORS GROWING IN MICE. | $330,000 | 2018 |
| THE JACKSON LABORATORYFARMINGTON, CT | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE FUNDS TO SUPPORT A STUDY WHERE PATIENTS WILL BE RECRUITED TO CONTRIBUTE TUMOR AND GUT MICROBE SAMPLES FOR SEQUENCING TO IDENTIFY INVOLVED MICROBES, AND WILL ALSO DEVELOP A MOUSE MODEL FOR TESTING CANDIDATES THAT WILL HAVE BROAD UTILITY BEYOND THE SCOPE OF THIS SPECIFIC PROJECT. | $307,500 | 2017 |
| THE JACKSON LABORATORYFARMINGTON, CT | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE FUNDS TO SUPPORT THE IDENTIFICATION OF A POTENTIALLY CURATIVE REGIMEN FOR TANDEM DUPLICATOR PHENOTYPE TRIPLE NEGATIVE BREAST CANCER TO BE TESTED IN A PANEL OF HUMAN TRIPLE NEGATIVE BREAST CANCER TUMORS GROWING IN MICE. | $282,000 | 2017 |
| THE JACKSON LABORATORYFARMINGTON, CT | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE FUNDS TO SUPPORT A STUDY WHERE PATIENTS WILL BE RECRUITED TO CONTRIBUTE TUMOR AND GUT MICROBE SAMPLES FOR SEQUENCING TO IDENTIFY INVOLVED MICROBES, AND WILL ALSO DEVELOP A MOUSE MODEL FOR TESTING CANDIDATES THAT WILL HAVE BROAD UTILITY BEYOND THE SCOPE OF THIS SPECIFIC PROJECT. | $280,000 | 2018 |
| MAYO CLINICJACKSONVILLE, FL | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE GIFT TO SUPPORT A PROJECT USING A NEW GENOMICS INTEGRATION TOOL TO INCREASE THE ACCURACY OF GENOMIC TESTING AND SIMPLIFY PRIORITIZATION OF TARGETED THERAPY STRATEGIES (INCLUDING IMMUNOTHERAPIES) - AND BY PRESCREENING THE EFFICACY OF THESE STRATEGIES USING A 3-DIMENSIONAL (3D) MICROCANCER NON-ANIMAL BASED RESEARCH MODEL. | $250,000 | 2019 |
| The Jackson LaboratoryFarmington, CT | The Benefactor desires that Grantee shall use the funds to support the identification of a potentially curative regimen for tandem duplicator phenotype triple negative breast cancer to be tested in a panel of human triple negative breast cancer tumors growing in mice. | $197,594 | 2016 |
| MDI Biological LaboratoryMatched to this organization because 3 grant-making charities wrote this name with its EIN. Source: Schedule I of their Form 990 returns, fiscal years 2020 to 2024. Counted Oct 9, 2026.Bar Harbor, ME | The Benefactor desires that Grantee shall use the funds to support research to define both a mechanism of action and a more effective treatment paradigm in molecular stimulation of the natural repair processes in the heart and other tissues. | $197,425 | 2016 |
| UNIVERSITY OF ARIZONATUCSON, AZ | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE GIFT TO IMPROVE THE DIAGNOSIS AND TREATMENT OF ATRIAL FIBRILLATION. TO DEVELOP PATIENT-SPECIFIC TARGETED NEXT-GENERATION GENE SEQUENCING FOR PREDICTING AND DIAGNOSING ATRIAL FIBRILLATION AND ESTABLISH A PATIENT-SPECIFIC STEM CELL PLATFORM FOR DEVELOPING PRECISION MEDICINE BASED TREATMENTS. | $175,006 | 2021 |
| UNIVERSITY OF ARIZONATUCSON, AZ | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE GIFT TO SEEK TO IMPROVE THE DIAGNOSIS AND TREATMENT OF ATRIAL FIBRILLATION. TODEVELOP PATIENT-SPECIFIC TARGETED NEXT-GENERATION GENE SEQUENCING FOR PREDICTING AND DIAGNOSING ATRIAL FIBRILLATION AND ESTABLISH A PATIENT-SPECIFIC STEM CELL PLATFORM FOR DEVELOPING PRECISION MEDICINE BASED TREATMENTS. | $174,994 | 2022 |
| HMH HOSPITALS CORPORATIONEDISON, NJ | YEAR 2 FUNDING - THIS PROJECT SEEKS TO FOCUS ON QUANTIFYING SELECTIVE PRESSURES APPLIED BY NUCLEOTIDE DEPLETION AND GENOMIC STRESS IN ORDER TO DISSECT THE EVOLUTIONARY DYNAMICS OF CANCER CELLS ACROSS MULTIPLE TUMOR TYPES, INCLUDING LEUKEMIA, LYMPHOMA, MYELOMA, COLORECTAL CANCER, MELANOMA, AND RETINOBLASTOMA. | $150,000 | 2024 |
| UNIVERSITY OF FLORIDA FOUNDATIONGAINESVILLE, FL | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE GIFT TO BROADEN THE DISCOVERY OF NEW PANCREATIC CANCER BIOMARKERS THROUGH GENOMIC SEQUENCING. BY SEQUENCING TUMOR AND NORMAL SAMPLES FROM OUR PATIENTS, WE CAN DETERMINE NOVEL CANCER DRIVERS INCLUDING MUTATIONS, FUSIONS, AND GENE EXPRESSION ALTERATIONS THAT DRIVE THESE CANCERS. NEW BIOMARKERS WILL INTRODUCE NEW POTENTIAL TARGETS FOR TREATMENT AND EARLY DETECTIONS. | $150,000 | 2021 |
| UNIVERSITY OF FLORIDA FOUNDATIONGAINESVILLE, FL | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE GIFT TO SUPPORT THE OFFERING OF GENETIC TESTING AND RELATED DOWNSTREAM SERVICES TO ALL PATIENTS DIAGNOSED WITH PANCREATIC CANCER AT UF HEALTH. | $150,000 | 2020 |
| UNIVERSITY OF FLORIDA FOUNDATIONGAINESVILLE, FL | YEAR 2 FUNDING - THIS PROJECT SEEKS TO IDENTIFY DEPENDENCIES OF TUMOR CELLS IN DEEP MARGINS BY PERFORMING SINGLE-CELL SEQUENCING ON LARGER COHORT OF TUMORS THE GRANTEE COLLECTED (N=28) AND TESTING THEIR FINDINGS IN MODEL SYSTEMS. THUS, THE STUDY WOULD OPEN NEW AVENUES FOR THERAPIES TARGETING SPECIFIC TRAITS WITHIN TUMOR CELLS DRIVING RECURRENCE, AND FOR IMPROVED STRATEGIES RELEASING THE HOST IMMUNE SYSTEM AGAINST GLIOBLASTOMA. | $149,345 | 2024 |
| ISRAEL CANCER RESEARCH FUNDNEW YORK, NY | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE GIFT TO ASK HOW DNA REPAIR IS ORCHESTRATED DESPITE THE PACKAGING OF DNA INTO CHROMATIN. SWI/SNF PROTEINS ESTABLISH AND MAINTAIN CHROMATIN STRUCTURE. SUBUNITS OF SWI/SNF PROTEINS ARE MUTATED IN 20% OF CANCERS, IMPLICATING THEM IN CARCINOGENESIS, AND MAKING THEM ATTRACTIVE CANDIDATES FOR CANCER-SPECIFIC AND SELECTIVE THERAPIES. DR. ADAR EXPECTS TO ESTABLISH THAT SWI/SNF REMODELERS FACILITATE SPECIFIC STEPS IN NUCLEOTIDE EXCISION REPAIR (NER) IN CHROMATIN TEMPLATES, AND THAT CANCER ASSOCIATED MUTANTS ARE DEFICIENT IN THIS FUNCTION. THIS NEW UNDERSTANDING OF SWI/SNF FUNCTIONS CAN THEN BE LEVERAGED TO DESIGN NEW CANCER DIAGNOSTICS AND CHEMOTHERAPEUTICS. | $148,500 | 2021 |
| THE JACKSON LABORATORYMatched to this organization because 33 grant-making charities wrote this name with its EIN. Source: Schedule I of their Form 990 returns, fiscal years 2020 to 2025. Counted Oct 9, 2026.BAR HARBOR, ME | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE GIFT TO INVESTIGATE AGING-RELATED RNA SPLICING ALTERATIONS TO REVEAL NOVEL BIOMARKERS FOR QUANTIFYING BREAST CANCER RISK AND NEW TARGETS FOR TREATING BREAST CANCER. | $135,000 | 2022 |
| UNIVERSITY OF NORTH FLORIDAJACKSONVILLE, FL | THE BENEFACTOR DESIRES THAT THE GRANTEE SHALL USE THE GIFT TO SUPPORT A 16 WEEK STUDY ON THE EFFECT OF FERMENTED FOODS ON THE GUT MICROBIOTA FOR PREVENTION OF CARDIOVASCULAR DISEASE TO HELP REDUCE THE MORTALITY RATE OF CARDIOVASCULAR DISEASE. | $128,449 | 2020 |
| 6.00 |
| $0 |
| Carolyn Tucker | EXEC. DIRECTOR | 40.00 | $0 |
| Paula Sprague | DIRECTOR | 5.00 | $0 |
Only shared inboxes and organization phone lines that appear in public filings are shown here. Contact details for named individuals are never published, even though the filing itself is public.
Nearest by size, location and giving pattern in the database. Geography weighs heavily. Treat it as a starting list, not a ranking of fit.
Form 990-PF · FY2023 · period ending Dec 31, 2023IRS bulk XML
Filing id 202541299349101429
Form 990-PF · FY2022 · period ending Dec 31, 2022
Filing id 202303429349100210
Form 990-PF · FY2021 · period ending Dec 31, 2021
Filing id 202310469349101406
Form 990-PF · FY2020 · period ending Dec 31, 2020
Filing id 202143199349107514
Form 990-PF · FY2019 · period ending Dec 31, 2019
Filing id 202003219349105435
Form 990-PF · FY2018 · period ending Dec 31, 2018
Filing id 201943189349101769
Form 990-PF · FY2017 · period ending Dec 31, 2017
Filing id 201823199349100447
Form 990-PF · FY2016 · period ending Dec 31, 2016
Filing id 201721959349100117
IRS filings are the source for every fact on this page. Nothing a model writes is ever a source; it can only point at a row here.